(Q47786408)

English

Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine

scientific article published on 10 May 2012

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/22572767

Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/22572767

Alzheimer's disease

0 references

Martin R. Farlow

3

object named as

Martin R Farlow

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/22572767

author name string

Rachelle S Doody

1

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/22572767

David S Geldmacher

2

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/22572767

Yijun Sun

4

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/22572767

Margaret Moline

5

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/22572767

Joan Mackell

6

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/22572767

publication date

10 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/22572767

Dementia and Geriatric Cognitive Disorders

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/22572767

33

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/22572767

2-3

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/22572767

164-173

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/22572767

Treatment options in Alzheimer's disease: maximizing benefit, managing expectations

1 reference

https://api.crossref.org/works/10.1159%2F000338236

21 January 2018

Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.

1 reference

https://api.crossref.org/works/10.1159%2F000338236

21 January 2018

Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil

1 reference

https://api.crossref.org/works/10.1159%2F000338236

21 January 2018

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1159%2F000338236

21 January 2018

Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.

1 reference

https://api.crossref.org/works/10.1159%2F000338236

21 January 2018

Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment.

1 reference

https://api.crossref.org/works/10.1159%2F000338236

21 January 2018

Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis.

1 reference

https://api.crossref.org/works/10.1159%2F000338236

21 January 2018

Long-term course and effectiveness of combination therapy in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1159%2F000338236

21 January 2018

Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1159%2F000338236

21 January 2018

Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1159%2F000338236

21 January 2018

The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner

1 reference

https://api.crossref.org/works/10.1159%2F000338236

21 January 2018

5-HT(3)-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile

1 reference

https://api.crossref.org/works/10.1159%2F000338236

21 January 2018

Identifiers

10.1159/000338236

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/22572767

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/22572767

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47786408&oldid=2170715047"